<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260616069824N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-11-21</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Swedish Massage on Balance and Nerve Symptoms in Patients with Type 2 Diabetes and Peripheral Neuropathy</public_title>
      <acronym></acronym>
      <scientific_title>Effects of Swedish Massage on Functional Balance, Proprioception, Active and Passive Ankle Range of Motion, and Sensory Neuropathic Symptoms in Patients with Type 2 Diabetes Mellitus and Peripheral Neuropathy: A Randomized Controlled Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-11-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>64</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/90921</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Method of Randomization: Stratified permuted block randomization with a 1:1 allocation ratio. Stratification will be based on two factors: sex (male/female) and diabetes duration (5–15 years vs. 16–25 years), yielding four strata. Within each stratum, variable block sizes of 4 and 6 will be used.
Unit of Randomization: Individual (each eligible patient is randomized independently).
Tools Used: Random Allocation Software will be used for sequence generation. Sequentially Numbered, Opaque, Sealed Envelopes (SNOSE) will be used for allocation concealment.
Sequence Construction: The sequence will be generated by an independent researcher not involved in screening, intervention, or outcome assessment, using a random seed to ensure a reproducible audit trail.
Allocation Concealment: Strictly enforced. The independent researcher will generate the sequence and prepare the sealed envelopes. Envelopes will be opened sequentially only after participant eligibility is confirmed and baseline assessments are completed, Blinding description: This is a single-blind (outcome assessor–blinded) randomized controlled trial. Because the intervention is a physical therapy (Swedish massage), participants and the care provider cannot be blinded; this is acknowledged, and participants are fully informed of their allocation at consent.

The outcome assessor and data collector are blinded; blinding is achieved by independent sequence generation and SNOSE preparation by a researcher not involved in screening, intervention, or assessment; envelope opening only after eligibility confirmation and completion of baseline assessments; assessments performed in a separate room with no access to allocation lists or the massage room; use of participant ID codes only on all forms and the electronic database; instruction to participants not to disclose their group; and documentation of any inadvertent unblinding. The data analyser is also blinded: the locked dataset is transferred with groups coded as "Group A" and "Group B," all analyses including MMRM are run on coded labels, and unblinding occurs only after the primary analysis is completed and signed off. Manuscript writers receive only unblinded aggregate results.</study_design>
      <phase>3</phase>
      <hc_freetext>Type 2 diabetes.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Participants will receive Swedish massage in addition to standard medical treatment. Massage will be applied from the lower legs to the toes for 30 minutes per session, three times per week for 4 weeks (12 sessions in total).Each session will include six sequential techniques: effleurage (10 minutes), consisting of gentle long strokes directed toward the heart; petrissage (10 minutes), involving gentle kneading, compression, and rolling movements; friction (5 minutes), involving circular movements over muscles and plantar fascia, avoiding bones; tapotement (2 minutes), using light rhythmic tapping, omitted in case of discomfort or fragile skin; vibration (2 minutes); and final effleurage (1 minute). Sweet almond oil will be used to reduce friction. Participants will be screened for almond allergy. Before each session, the lower limbs will be examined for skin injuries, edema, acute inflammation, or infection. Massage pressure will be gradually adjusted according to individual tolerance. Massage will be performed by a trained and certified therapist experienced in Swedish massage and diabetic neuropathy precautions. Intervention 2: Control group: Participants will continue their standard medical treatment and routine care prescribed by their treating endocrinologist throughout the study period. No massage intervention will be provided. Medications used for glycemic control, blood pressure, lipid management, and other related conditions will be continued and recorded.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is The project data belongs to Isfahan University of Medical Sciences and contains confidential information of patients</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Hadi Salavati</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Isfahan Endocrine and Metabolism Research Center, Sedigheh Tahereh Comprehensive Rehabilitation and Medical Center, Khorram Street, Jmohouri Eslami Square</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8187698191</zip>
        <telephone>+98 913 800 6518</telephone>
        <email>mohammadhadisalavati78@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Hadi Salavati</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hezar Jarib Street</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>81746-73461</zip>
        <telephone>+98 913 800 6518</telephone>
        <email>mohammadhadisalavati78@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 55 and 75 years.
Both male and female patients.
Confirmed diagnosis of type 2 diabetes mellitus.
Diabetes duration between 5 and 25 years.
Confirmed diabetic peripheral neuropathy (MNSI score ≥ 7).
HbA1c between 7% and 9.5%.
Stable medication regimen for at least 8 weeks before enrollment.
Ability and willingness to participate and complete follow-up.</inclusion_criteria>
      <agemin>55 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of deep vein thrombosis or severe peripheral arterial disease (ABI &lt; 0.8).
Active wound, infection, or severe Charcot neuroarthropathy.
Severe joint deformity or recent major lower limb surgery.
Non-diabetic neurological diseases affecting balance.
Stage 4 or 5 renal failure (eGFR &lt; 30 mL/min/1.73m²).
Receiving massage or manual physiotherapy in the past 3 months.
Known allergy to almond or nut oils (massage oil).</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E08.21</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Diabetes mellitus due to underlying condition with diabetic nephropathy</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Participants will receive Swedish massage in addition to standard medical treatment. Massage will be applied from the lower legs to the toes for 30 minutes per session, three times per week for 4 weeks (12 sessions in total).Each session will include six sequential techniques: effleurage (10 minutes), consisting of gentle long strokes directed toward the heart; petrissage (10 minutes), involving gentle kneading, compression, and rolling movements; friction (5 minutes), involving circular movements over muscles and plantar fascia, avoiding bones; tapotement (2 minutes), using light rhythmic tapping, omitted in case of discomfort or fragile skin; vibration (2 minutes); and final effleurage (1 minute). Sweet almond oil will be used to reduce friction. Participants will be screened for almond allergy. Before each session, the lower limbs will be examined for skin injuries, edema, acute inflammation, or infection. Massage pressure will be gradually adjusted according to individual tolerance. Massage will be performed by a trained and certified therapist experienced in Swedish massage and diabetic neuropathy precautions.</i_keyword>
      <i_keyword>Control group: Participants will continue their standard medical treatment and routine care prescribed by their treating endocrinologist throughout the study period. No massage intervention will be provided. Medications used for glycemic control, blood pressure, lipid management, and other related conditions will be continued and recorded.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Functional balance, assessed by the mean time required to complete the Timed Up and Go test, measured in seconds. Timepoint: At baseline (before intervention), after the third massage session (or the corresponding time point in the control group), immediately after completion of the 4-week intervention, and one month after intervention completion. Method of measurement: Timed Up and Go test. The time required to complete the test will be measured and recorded in seconds.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Michigan Neuropathy Screening Instrument questionnaire score, ranging from 0 to 15. Timepoint: At baseline before intervention, after the third massage session (or the corresponding time point in the control group), at the end of the 4 week intervention, and one month after intervention completion. Method of measurement: Michigan Neuropathy Screening Instrument questionnaire. The total questionnaire score will be calculated and recorded.</sec_outcome>
      <sec_outcome>Severity of sensory neuropathic symptoms, measured using a Visual Analogue Scale, with scores ranging from 0 to 10. Timepoint: At baseline before intervention, after the third massage session (or the corresponding time point in the control group), at the end of the 4 week intervention, and one month after intervention completion. Method of measurement: Visual Analogue Scale for assessing the severity of sensory neuropathic symptoms. Symptoms will be assessed and scored on a 0 to 10 scale.</sec_outcome>
      <sec_outcome>Ankle proprioception, assessed by the Joint Position Reproduction test and recorded in degrees. Timepoint: At baseline before intervention, after the third massage session (or the corresponding time point in the control group), at the end of the 4 week intervention, and one month after intervention completion. Method of measurement: Joint Position Reproduction test for evaluating ankle proprioception. Measurements will be recorded in degrees.</sec_outcome>
      <sec_outcome>Active range of motion of the ankle joint, measured in degrees. Timepoint: At baseline before intervention, after the third massage session (or the corresponding time point in the control group), at the end of the 4 week intervention, and one month after intervention completion. Method of measurement: Goniometer measurement of active ankle joint range of motion, recorded in degrees.</sec_outcome>
      <sec_outcome>Passive range of motion of the ankle joint, measured in degrees. Timepoint: At baseline before intervention, after the third massage session (or the corresponding time point in the control group), at the end of the 4 week intervention, and one month after intervention completion. Method of measurement: Goniometer measurement of passive ankle joint range of motion, recorded in degrees.</sec_outcome>
      <sec_outcome>Blood pressure level, measured in millimeters of mercury. Timepoint: At baseline before intervention and at the end of the 4 week intervention. Method of measurement: Blood pressure measurement, with values recorded in millimeters of mercury.</sec_outcome>
      <sec_outcome>Laboratory metabolic parameters, including glycated hemoglobin, total cholesterol, triglycerides, high density lipoprotein cholesterol, and low density lipoprotein cholesterol. Timepoint: At baseline before intervention and at the end of the 4 week intervention. Method of measurement: Laboratory measurement of glycated hemoglobin, total cholesterol, triglycerides, high density lipoprotein cholesterol, and low density lipoprotein cholesterol. Glycated hemoglobin will be reported as a percentage and lipid parameters in milligrams per deciliter.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-06-10</approval_date>
        <contact_name>Research Ethics Committee of the "Alzahra Research Centers</contact_name>
        <contact_address>Hezar jerib street Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
